Mounjaro: Type 2 Diabetes Treatment with Thyroid Cancer Risk

Mounjaro (tirzepatide) is a prescription medication approved for managing blood sugar in adults and children aged 10 and older with type 2 diabetes. It is administered via weekly subcutaneous injections.

The medication carries a boxed warning from the FDA regarding an increased risk of thyroid cancer, specifically medullary thyroid carcinoma (MTC), observed in animal studies. It is not yet established if this risk extends to humans.

Patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) are advised against using Mounjaro. Monitoring for symptoms such as neck lumps, difficulty swallowing, or hoarseness is recommended during treatment.

Common side effects include gastrointestinal issues like nausea and diarrhea. Serious potential side effects include pancreatitis and gallbladder problems.

Mounjaro is not FDA-approved for weight loss, though some patients may experience it.